Lysyl oxidase-like 2 is highly expressed in colorectal cancer cells and promotes the development of colorectal cancer

Cui,Ximao; Wang,Guanghui; Shen,Wenbin; Huang,Zhenyu; He,Hailan; Cui,Long

doi:10.3892/or.2018.6452

Lysyl oxidase-like 2 is highly expressed in colorectal cancer cells and promotes the development of colorectal cancer

Authors:
- Ximao Cui
- Guanghui Wang
- Wenbin Shen
- Zhenyu Huang
- Hailan He
- Long Cui
View Affiliations

Affiliations: Department of Colorectal and Anal Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, P.R. China
Published online on: May 21, 2018 https://doi.org/10.3892/or.2018.6452
Pages: 932-942

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer (CRC) is the third most common type of cancer. In the present study, the expression and intracellular localization of lysyl oxidase-like 2 (LOXL2) protein in CRC were examined. Quantitative polymerase chain reaction and western blot analysis of LOXL2 mRNA and protein expression was performed for 40 pairs of CRC tumor and normal mucosa tissue samples. The immunohistochemical staining of tissue microarrays was performed to detect LOXL2 protein expression. LOXL2 was highly expressed in the extracellular matrix and CRC cells. The positive expression of LOXL2 in CRC cells was significantly associated with the tumor tumor-node metastasis stage and distant metastasis, while elevated LOXL2 expression within the CRC cells was an independent prognostic factor in patients with CRC. The knockdown of LOXL2 impaired the proliferative and migratory abilities of CRC cells in vitro and in vivo, and induced cell cycle arrest and apoptosis. These findings indicated that LOXL2 might have an important role in CRC.

View Figures

View References

1	International Agency for Research on Cancer: Population Fact Sheets: World. http://gco.iarc.fr/today/fact-sheets-populations?population=900&sex=0July 25–2017.
2	Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, et al: Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 62:220–241. 2012. View Article : Google Scholar : PubMed/NCBI
3	Sankaranarayanan R, Swaminathan R, Brenner H, Chen K, Chia KS, Chen JG, Law SC, Ahn YO, Xiang YB, Yeole BB, et al: Cancer survival in Africa, Asia, and Central America: A population-based study. Lancet Oncol. 11:165–173. 2010. View Article : Google Scholar : PubMed/NCBI
4	Heald RJ and Ryall RD: Recurrence and survival after total mesorectal excision for rectal cancer. Lancet. 1:1479–1482. 1986. View Article : Google Scholar : PubMed/NCBI
5	van Gijn W, Marijnen CAM, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, Rutten HJ, Påhlman L, Glimelius B and van de Velde CJ; Dutch Colorectal Cancer Group: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 12:575–582. 2011. View Article : Google Scholar : PubMed/NCBI
6	Polónia A, Coimbra M, Reis S, Tavares A, Raimundo A, Santos LL, Jeronimo C and Henrique RM: Expression of histone modifying enzymes and histone post-translational marks in colorectal cancer. Virchows Arch. 463:1252013.
7	Barker HE, Cox TR and Erler JT: The rationale for targeting the LOX family in cancer. Nat Rev Cancer. 12:540–552. 2012. View Article : Google Scholar : PubMed/NCBI
8	Ikenaga N, Peng ZW, Vaid KA, Liu SB, Yoshida S, Sverdlov DY, Mikels-Vigdal A, Smith V, Schuppan D and Popov YV: Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal. Gut. 66:1697–1708. 2017. View Article : Google Scholar : PubMed/NCBI
9	Yang J, Savvatis K, Kang JS, Fan P, Zhong H, Schwartz K, Barry V, Mikels-Vigdal A, Karpinski S, Kornyeyev D, et al: Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment. Nat Commun. 7:137102016. View Article : Google Scholar : PubMed/NCBI
10	Wu L and Zhu Y: The function and mechanisms of action of LOXL2 in cancer (Review). Int J Mol Med. 36:1200–1204. 2015. View Article : Google Scholar : PubMed/NCBI
11	Park JS, Lee JH, Lee YS, Kim JK, Dong SM and Yoon DS: Emerging role of LOXL2 in the promotion of pancreas cancer metastasis. Oncotarget. 7:42539–42552. 2016.PubMed/NCBI
12	Torres S, Garcia-Palmero I, Herrera M, Bartolomé RA, Peña C, Fernandez-Aceñero MJ, Padilla G, Peláez-García A, Lopez-Lucendo M, Rodriguez-Merlo R, et al: LOXL2 is highly expressed in cancer-associated fibroblasts and associates to poor colon cancer survival. Clin Cancer Res. 21:4892–4902. 2015. View Article : Google Scholar : PubMed/NCBI
13	Wong CC, Tse AP, Huang YP, Zhu YT, Chiu DK, Lai RK, Au SL, Kai AK, Lee JM, Wei LL, et al: Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma. Hepatology. 60:1645–1658. 2014. View Article : Google Scholar : PubMed/NCBI
14	Moreno-Bueno G, Salvador F, Martín A, Floristán A, Cuevas EP, Santos V, Montes A, Morales S, Castilla MA, Rojo-Sebastián A, et al: Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomas. EMBO Mol Med. 3:528–544. 2011. View Article : Google Scholar : PubMed/NCBI
15	Fu J, Tang W, Du P, Wang G, Chen W, Li J, Zhu Y, Gao J and Cui L: Identifying microRNA-mRNA regulatory network in colorectal cancer by a combination of expression profile and bioinformatics analysis. BMC Syst Biol. 6:682012. View Article : Google Scholar : PubMed/NCBI
16	Cui X, Liu B, Zheng S, Dong K and Dong R: Genome-wide analysis of DNA methylation in hepatoblastoma tissues. Oncol Lett. 12:1529–1534. 2016. View Article : Google Scholar : PubMed/NCBI
17	Wang G, Shen W, Liu CY, Liu Y, Wu T, Cui X, Yu T, Zhu Y, Song J, Du P, et al: Phosphorylase kinase β affects colorectal cancer cell growth and represents a novel prognostic biomarker. J Cancer Res Clin Oncol. 143:971–980. 2017. View Article : Google Scholar : PubMed/NCBI
18	Cui X, Yang Y, Jia D, Jing Y, Zhang S, Zheng S, Cui L, Dong R and Dong K: Downregulation of bone morphogenetic protein receptor 2 promotes the development of neuroblastoma. Biochem Biophys Res Commun. 483:609–616. 2017. View Article : Google Scholar : PubMed/NCBI
19	Wiederschain D, Wee S, Chen L, Loo A, Yang G, Huang A, Chen Y, Caponigro G, Yao YM, Lengauer C, et al: Single-vector inducible lentiviral RNAi system for oncology target validation. Cell Cycle. 8:498–504. 2009. View Article : Google Scholar : PubMed/NCBI
20	Liu CY, Yu T, Huang Y, Cui L and Hong W: ETS (E26 transformation-specific) up-regulation of the transcriptional co-activator TAZ promotes cell migration and metastasis in prostate cancer. J Biol Chem. 292:9420–9430. 2017. View Article : Google Scholar : PubMed/NCBI
21	Liu Y, Wang G, Yang Y, Mei Z, Liang Z, Cui A, Wu T, Liu CY and Cui L: Increased TEAD4 expression and nuclear localization in colorectal cancer promote epithelial-mesenchymal transition and metastasis in a YAP-independent manner. Oncogene. 35:2789–2800. 2016. View Article : Google Scholar : PubMed/NCBI
22	Findlay VJ, Wang C, Nogueira LM, Hurst K, Quirk D, Ethier SP, Staveley O'Carroll KF, Watson DK and Camp ER: SNAI2 modulates colorectal cancer 5-fluorouracil sensitivity through miR145 repression. Mol Cancer Ther. 13:2713–2726. 2014. View Article : Google Scholar : PubMed/NCBI
23	Terret ME, Lefebvre C, Djiane A, Rassinier P, Moreau J, Maro B and Verlhac MH: DOC1R: A MAP kinase substrate that control microtubule organization of metaphase II mouse oocytes. Development. 130:5169–5177. 2003. View Article : Google Scholar : PubMed/NCBI
24	Liu SB, Ikenaga N, Peng ZW, Sverdlov DY, Greenstein A, Smith V, Schuppan D and Popov Y: Lysyl oxidase activity contributes to collagen stabilization during liver fibrosis progression and limits spontaneous fibrosis reversal in mice. FASEB J. 30:1599–1609. 2016. View Article : Google Scholar : PubMed/NCBI
25	Barry-Hamilton V, Spangler R, Marshall D, McCauley S, Rodriguez HM, Oyasu M, Mikels A, Vaysberg M, Ghermazien H, Wai C, et al: Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med. 16:1009–1017. 2010. View Article : Google Scholar : PubMed/NCBI
26	Barker HE, Chang J, Cox TR, Lang G, Bird D, Nicolau M, Evans HR, Gartland A and Erler JT: LOXL2-mediated matrix remodeling in metastasis and mammary gland involution. Cancer Res. 71:1561–1572. 2011. View Article : Google Scholar : PubMed/NCBI
27	Kouhkan F, Motovali-Bashi M and Hojati Z: The influence of interstitial collagenase-1 genotype polymorphism on colorectal cancer risk in Iranian population. Cancer Invest. 26:836–842. 2008. View Article : Google Scholar : PubMed/NCBI
28	Park PG, Jo SJ, Kim MJ, Kim HJ, Lee JH, Park CK, Kim H, Lee KY, Kim H, Park JH, et al: Role of LOXL2 in the epithelial-mesenchymal transition and colorectal cancer metastasis. Oncotarget. 8:80325–80335. 2017.PubMed/NCBI
29	Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
30	Peinado H, Del Carmen Iglesias-de la Cruz M, Olmeda D, Csiszar K, Fong KS, Vega S, Nieto MA, Cano A and Portillo F: A molecular role for lysyl oxidase-like 2 enzyme in snail regulation and tumor progression. EMBO J. 24:3446–3458. 2005. View Article : Google Scholar : PubMed/NCBI
31	Hecht JR, Benson AB III, Vyushkov D, Yang Y, Bendell J and Verma U: A phase II, randomized, double-blind, placebo-controlled study of simtuzumab in combination with FOLFIRI for the second-line treatment of metastatic KRAS mutant colorectal adenocarcinoma. Oncologist. 22:243–e23. 2017. View Article : Google Scholar : PubMed/NCBI